Logo image of BCEL

ATRECA INC - A (BCEL) Stock Fundamental Analysis

NASDAQ:BCEL - Nasdaq - US04965G1094 - Common Stock - Currency: USD

0.15  -0.02 (-11.76%)

After market: 0.1399 -0.01 (-6.73%)

Fundamental Rating

2

Overall BCEL gets a fundamental rating of 2 out of 10. We evaluated BCEL against 561 industry peers in the Biotechnology industry. BCEL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BCEL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BCEL had negative earnings in the past year.
In the past year BCEL has reported a negative cash flow from operations.
In the past 5 years BCEL always reported negative net income.
In the past 5 years BCEL always reported negative operating cash flow.
BCEL Yearly Net Income VS EBIT VS OCF VS FCFBCEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of BCEL (-371.75%) is worse than 97.11% of its industry peers.
With a Return On Equity value of -905.28%, BCEL is not doing good in the industry: 85.03% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -371.75%
ROE -905.28%
ROIC N/A
ROA(3y)-49.68%
ROA(5y)-42.94%
ROE(3y)-76.72%
ROE(5y)-59.76%
ROIC(3y)N/A
ROIC(5y)N/A
BCEL Yearly ROA, ROE, ROICBCEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 -20 -40 -60 -80 -100

1.3 Margins

BCEL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCEL Yearly Profit, Operating, Gross MarginsBCEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, BCEL has more shares outstanding
BCEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BCEL Yearly Shares OutstandingBCEL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 10M 20M 30M
BCEL Yearly Total Debt VS Total AssetsBCEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -37.58, we must say that BCEL is in the distress zone and has some risk of bankruptcy.
BCEL's Altman-Z score of -37.58 is on the low side compared to the rest of the industry. BCEL is outperformed by 93.71% of its industry peers.
BCEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -37.58
ROIC/WACCN/A
WACCN/A
BCEL Yearly LT Debt VS Equity VS FCFBCEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 0 100M 200M

2.3 Liquidity

BCEL has a Current Ratio of 1.58. This is a normal value and indicates that BCEL is financially healthy and should not expect problems in meeting its short term obligations.
BCEL's Current ratio of 1.58 is on the low side compared to the rest of the industry. BCEL is outperformed by 83.50% of its industry peers.
BCEL has a Quick Ratio of 1.58. This is a normal value and indicates that BCEL is financially healthy and should not expect problems in meeting its short term obligations.
BCEL has a Quick ratio of 1.58. This is amonst the worse of the industry: BCEL underperforms 81.97% of its industry peers.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 1.58
BCEL Yearly Current Assets VS Current LiabilitesBCEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

BCEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.35%, which is quite impressive.
EPS 1Y (TTM)29.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BCEL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.29% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.77%
EPS Next 2Y28.42%
EPS Next 3Y18.1%
EPS Next 5Y9.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCEL Yearly Revenue VS EstimatesBCEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2028 2M 4M 6M 8M 10M
BCEL Yearly EPS VS EstimatesBCEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BCEL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BCEL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCEL Price Earnings VS Forward Price EarningsBCEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCEL Per share dataBCEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as BCEL's earnings are expected to grow with 18.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.42%
EPS Next 3Y18.1%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BCEL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATRECA INC - A

NASDAQ:BCEL (3/18/2024, 8:00:01 PM)

After market: 0.1399 -0.01 (-6.73%)

0.15

-0.02 (-11.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13 2024-03-13/amc
Earnings (Next)05-08 2024-05-08/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners11.24%
Ins Owner Change0%
Market Cap5.94M
Analysts82
Price Target5.61 (3640%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.92%
Min EPS beat(2)0.5%
Max EPS beat(2)15.33%
EPS beat(4)4
Avg EPS beat(4)8.36%
Min EPS beat(4)0.5%
Max EPS beat(4)15.33%
EPS beat(8)7
Avg EPS beat(8)8.6%
EPS beat(12)9
Avg EPS beat(12)5.63%
EPS beat(16)11
Avg EPS beat(16)3.89%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)69.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.89%
EPS NY rev (1m)-204.48%
EPS NY rev (3m)-4.48%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-1.95
EYN/A
EPS(NY)-0.88
Fwd EYN/A
FCF(TTM)-1.65
FCFYN/A
OCF(TTM)-1.64
OCFYN/A
SpS0
BVpS0.27
TBVpS0.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -371.75%
ROE -905.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.68%
ROA(5y)-42.94%
ROE(3y)-76.72%
ROE(5y)-59.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.38%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.58
Quick Ratio 1.58
Altman-Z -37.58
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)332.95%
Cap/Depr(5y)265.32%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35%
EPS Next Y16.77%
EPS Next 2Y28.42%
EPS Next 3Y18.1%
EPS Next 5Y9.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.79%
EBIT Next 3Y6.88%
EBIT Next 5Y-0.01%
FCF growth 1Y31.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.43%
OCF growth 3YN/A
OCF growth 5YN/A